Overview
- Editors:
-
-
Michael F. Powell
-
Genentech, Inc., South San Francisco, USA
-
Mark J. Newman
-
Vaxcel, Inc., Norcross, USA
Access this book
Other ways to access
Table of contents (41 chapters)
-
- Lendon G. Payne, Sharon A. Jenkins, Alexander Andrianov, Bryan E. Roberts
Pages 473-493
-
- J. Terry Ulrich, Kent R. Myers
Pages 495-524
-
- Charlotte Read Kensil, Jia-Yan Wu, Sean Soltysik
Pages 525-541
-
- G. F. Rimmelzwaan, A. D. M. E. Osterhaus
Pages 543-558
-
-
-
-
- Penny Dong, Carsten Brunn, Rodney J. Y. Ho
Pages 625-643
-
-
- Lawrence B. Lachman, Li-Chen N. Shih, Xiao-Mei Rao, Stephen E. Ullrich, Jeffrey L. Cleland
Pages 659-671
-
- Peter J. Kniskern, Stephen Marburg, Ronald W. Ellis
Pages 673-694
-
-
- Richard T. Coughlin, Jianneng Ma, Daniel E. Cox
Pages 719-735
-
- Robert B. Grieve, Nancy Wisnewski, Glenn R. Frank, Cynthia A. Tripp
Pages 737-768
-
- Sally E. Adams, Alan J. Kingsman
Pages 769-786
-
- Stephen L. Hoffman, John B. Sacci Jr.
Pages 787-802
-
- Bernardetta Nardelli, James P. Tam
Pages 803-819
-
- Mary Kate Hart, Thomas J. Palker, Barton F. Haynes
Pages 821-845
-
- Robert W. Chesnut, Alessandro Sette, Esteban Celis, Peggy Wentworth, Ralph T. Kubo, Jeff Alexander et al.
Pages 847-874
-
- John Samuel, B. Michael Longenecker
Pages 875-890
About this book
When my interest was first drawn to the phenomenon of vaccination for virus diseases in the late 1930s, the state of the art and the science of vaccine design was not far advanced beyond the time of Jenner at the end of the 18th century and of Pasteur a century later. In the 1930s it was still believed that for the induction of immunity to a virus-caused disease the experience of infection was required, but not for a toxin-caused disease such as diphtheria or tetanus, for which a chemically detoxified antigen was effective for immu nization. This prompted the question as to whether it might be possible to produce a similar effect for virus diseases using nonreplicating antigens. When in the 1930s and 1940s it was found possible to propagate influenza viruses in the chick embryo, protective effects could be induced without the need to experience infection by the use of a sufficient dose of a noninfectious influenza virus preparation. Later in the 1940s, it became possible to propagate polio and other viruses in cultures of human and monkey tissue and to immunize against other virus diseases in the same way. Later, with the advent of the era of molecular biology and genetic engineering, antigens and vaccines could be produced in new and creative ways, using either replicating or nonreplicating forms of the appropriate antigens for inducing a dose-related protective state.
Reviews
`This book should be very valuable to anyone interested in the basic design of vaccine strategies or the preclinical evaluation of novel vaccines and adjuvants.'
Doody's Journal
`I have little doubt that this book will become a standard reference for future development of vaccine formulations.'
European Journal of Pharmaceutics and Biopharmaceutics
Editors and Affiliations
-
Genentech, Inc., South San Francisco, USA
Michael F. Powell
-
Vaxcel, Inc., Norcross, USA
Mark J. Newman